Cargando…
First-line treatment of acute lymphoblastic leukemia with pegasparaginase
Acute lymphoblastic leukemia (ALL) accounts for almost 4000 cases annually in the United States, approximately two thirds of which are in children and adolescents. Treatment results of ALL have improved considerably in the past decade, due to an optimal stratification of patients and a rational use...
Autores principales: | Masetti, Riccardo, Pession, Andrea |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726072/ https://www.ncbi.nlm.nih.gov/pubmed/19707421 |
Ejemplares similares
-
Cerebrospinal fluid xanthochromia after pegasparaginase hepatotoxicity in B‐cell acute lymphoblastic leukemia
por: Moia, Riccardo, et al.
Publicado: (2020) -
The Role of HDACs Inhibitors in Childhood and Adolescence Acute
Leukemias
por: Masetti, Riccardo, et al.
Publicado: (2011) -
Acute Myeloid Leukemia in Infants: Biology and Treatment
por: Masetti, Riccardo, et al.
Publicado: (2015) -
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
por: Kloos, Robin Q.H., et al.
Publicado: (2020) -
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
por: Kloos, Robin Q.H., et al.
Publicado: (2023)